$MYO
MYOMO, INC.

2019 Q2 Form 10-Q Financial Statement

#000156459019030866 Filed on August 08, 2019

View on sec.gov

Income Statement

Concept 2019 Q2
Revenue $880.3K
YoY Change 39.21%
Cost Of Revenue $125.0K
YoY Change -37.64%
Gross Profit $755.3K
YoY Change 74.88%
Gross Profit Margin 85.8%
Selling, General & Admin $2.800M
YoY Change 6.59%
% of Gross Profit 370.71%
Research & Development $535.9K
YoY Change 10.05%
% of Gross Profit 70.95%
Depreciation & Amortization $23.45K
YoY Change 17.25%
% of Gross Profit 3.1%
Operating Expenses $3.336M
YoY Change 7.13%
Operating Profit -$2.581M
YoY Change -3.78%
Interest Expense $141.0K
YoY Change 182.93%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$2.565M
YoY Change -2.46%
Income Tax
% Of Pretax Income
Net Earnings -$2.565M
YoY Change -2.44%
Net Earnings / Revenue -291.4%
Basic Earnings Per Share
Diluted Earnings Per Share -$4.500M
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $6.669M
YoY Change -42.9%
Cash & Equivalents $6.669M
Short-Term Investments
Other Short-Term Assets $817.5K
YoY Change 77.71%
Inventory $349.2K
Prepaid Expenses
Receivables $331.0K
Other Receivables $0.00
Total Short-Term Assets $8.167M
YoY Change -36.09%
LONG-TERM ASSETS
Property, Plant & Equipment $192.6K
YoY Change 17.53%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $183.4K
YoY Change 52.83%
Total Long-Term Assets $376.0K
YoY Change 30.6%
TOTAL ASSETS
Total Short-Term Assets $8.167M
Total Long-Term Assets $376.0K
Total Assets $8.543M
YoY Change -34.63%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $429.5K
YoY Change 26.31%
Accrued Expenses $947.4K
YoY Change -10.62%
Deferred Revenue $40.00
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.436M
YoY Change -8.56%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $0.00
YoY Change -100.0%
Total Long-Term Liabilities $0.00
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.436M
Total Long-Term Liabilities $0.00
Total Liabilities $1.436M
YoY Change -11.13%
SHAREHOLDERS EQUITY
Retained Earnings -$50.58M
YoY Change 26.61%
Common Stock $57.69M
YoY Change 4648521.51%
Preferred Stock
YoY Change
Treasury Stock (at cost) $6.464K
YoY Change 0.0%
Treasury Stock Shares
Shareholders Equity $7.061M
YoY Change
Total Liabilities & Shareholders Equity $8.543M
YoY Change -34.63%

Cashflow Statement

Concept 2019 Q2
OPERATING ACTIVITIES
Net Income -$2.565M
YoY Change -2.44%
Depreciation, Depletion And Amortization $23.45K
YoY Change 17.25%
Cash From Operating Activities -$2.288M
YoY Change -2.24%
INVESTING ACTIVITIES
Capital Expenditures -$29.50K
YoY Change 47.5%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$29.50K
YoY Change 47.5%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -247.7K
YoY Change 395.3%
NET CHANGE
Cash From Operating Activities -2.288M
Cash From Investing Activities -29.50K
Cash From Financing Activities -247.7K
Net Change In Cash -2.565M
YoY Change 6.42%
FREE CASH FLOW
Cash From Operating Activities -$2.288M
Capital Expenditures -$29.50K
Free Cash Flow -$2.258M
YoY Change -2.67%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
470944526
dei Entity Address Address Line1
EntityAddressAddressLine1
One Broadway
dei Entity Address Address Line2
EntityAddressAddressLine2
14th Floor
dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
dei Entity Address State Or Province
EntityAddressStateOrProvince
Massachusetts
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02142
dei City Area Code
CityAreaCode
617
dei Local Phone Number
LocalPhoneNumber
996-9058
CY2019Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6668871
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6540794
CY2019Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
331013
CY2018Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
382258
CY2019Q2 us-gaap Inventory Net
InventoryNet
349196
CY2018Q4 us-gaap Inventory Net
InventoryNet
256149
CY2019Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
817478
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
695276
CY2019Q2 us-gaap Assets Current
AssetsCurrent
8166558
CY2018Q4 us-gaap Assets Current
AssetsCurrent
7874477
CY2019Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
75000
CY2018Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
75000
CY2019Q2 us-gaap Deferred Offering Costs
DeferredOfferingCosts
108402
CY2018Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
144582
CY2019Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
192574
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
187513
CY2019Q2 us-gaap Assets
Assets
8542534
CY2018Q4 us-gaap Assets
Assets
8281572
CY2019Q2 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
1376878
CY2018Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
1743427
CY2019Q2 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
58477
CY2018Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
3661
CY2019Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
570
CY2018Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1990
CY2019Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
40
CY2018Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
106609
CY2019Q2 us-gaap Liabilities Current
LiabilitiesCurrent
1435965
CY2019Q2 us-gaap Liabilities
Liabilities
1435965
CY2018Q4 us-gaap Liabilities
Liabilities
1855687
CY2019Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q2 us-gaap Common Stock Value
CommonStockValue
1713
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
1245
CY2019Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
57687680
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
51720630
CY2019Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-50576360
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-45289526
CY2019Q2 us-gaap Treasury Stock Value
TreasuryStockValue
6464
CY2018Q4 us-gaap Treasury Stock Value
TreasuryStockValue
6464
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
7106569
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
6425885
CY2019Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
8542534
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
8281572
CY2019Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2019Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
17139691
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12450187
CY2019Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
17138883
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12449379
CY2019Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
880349
CY2018Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
632369
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1710415
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
945548
CY2019Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
17105527
CY2018Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
12407758
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
16033584
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.15
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.41
CY2019Q1 us-gaap Cumulative Effect On Retained Earnings Net Of Tax1
CumulativeEffectOnRetainedEarningsNetOfTax1
-123447
CY2019Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
5648928
CY2019Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-72115
CY2019Q1 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
1
CY2019Q1 myo Warrants Issued As Offering Costs And Recorded As Derivative Liability
WarrantsIssuedAsOfferingCostsAndRecordedAsDerivativeLiability
196236
CY2019Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
396325
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-2598060
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
9481281
CY2019Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
15
CY2019Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-6356
CY2019Q2 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
-72
CY2019Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
197028
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
12445778
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3439161
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
13924072
CY2018Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-5041
CY2018Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2
CY2018Q2 myo Common Stock Issued For Warrants Exercised
CommonStockIssuedForWarrantsExercised
5901
CY2018Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-63149
CY2018Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
336355
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-2345402
CY2018Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
155725
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
11451098
CY2019Q1 myo Offering Cost From Sale Of Shares
OfferingCostFromSaleOfShares
710572
CY2019Q2 myo Offering Cost From Sale Of Shares
OfferingCostFromSaleOfShares
CY2018Q1 myo Offering Cost From Sale Of Shares
OfferingCostFromSaleOfShares
CY2018Q2 myo Offering Cost From Sale Of Shares
OfferingCostFromSaleOfShares
CY2019Q1 us-gaap Restricted Stock Shares Issued Net Of Shares For Tax Withholdings
RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings
45459
CY2019Q2 us-gaap Restricted Stock Shares Issued Net Of Shares For Tax Withholdings
RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings
7032
CY2018Q1 us-gaap Restricted Stock Shares Issued Net Of Shares For Tax Withholdings
RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings
17570
CY2018Q2 us-gaap Restricted Stock Shares Issued Net Of Shares For Tax Withholdings
RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings
1692
us-gaap Profit Loss
ProfitLoss
-5163387
us-gaap Profit Loss
ProfitLoss
-4974963
us-gaap Depreciation
Depreciation
45076
us-gaap Depreciation
Depreciation
28900
us-gaap Share Based Compensation
ShareBasedCompensation
593353
us-gaap Share Based Compensation
ShareBasedCompensation
492080
us-gaap Inventory Write Down
InventoryWriteDown
28887
myo Fair Value Of Warrants And Derivative Liabilities
FairValueOfWarrantsAndDerivativeLiabilities
141420
myo Fair Value Of Warrants And Derivative Liabilities
FairValueOfWarrantsAndDerivativeLiabilities
17968
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-2481
us-gaap Other Noncash Expense
OtherNoncashExpense
12606
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-51245
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
87912
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
195397
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
109498
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
161014
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
74507
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-23574
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-366549
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
122099
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-1420
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-17466
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-106569
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5407421
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4610348
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
34903
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
81457
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-34903
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-81457
myo Proceeds From Payments For Issuance Costs
ProceedsFromPaymentsForIssuanceCosts
-49042
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
78542
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
68190
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
15
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
3556391
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
5648928
CY2018Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
11758729
myo Inventory Capitalized As Sales Demo Equipment
InventoryCapitalizedAsSalesDemoEquipment
34142
myo Issuance Of Warrants Recorded As Derivative Liability
IssuanceOfWarrantsRecordedAsDerivativeLiability
196236
us-gaap Nature Of Operations
NatureOfOperations
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Note 1 &#8212; Description of Business</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Myomo Inc. (&#8220;Myomo&#8221; or the Company&#8221;) is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro &#174; myoelectric upper limb orthosis product is registered with the U.S. Food and Drug Administration as a Class&#160;II medical device. The Company sells its products to orthotics and prosthetics (O&amp;P) providers, the Veterans Health Administration, rehabilitation hospitals, and through distributors. Recently, the Company has begun providing devices directly to patients and billing their insurance companies directly, often utilizing the clinical services of O&amp;P providers for which they are paid a fee. The Company was incorporated in the State of Delaware on September&#160;1, 2004 and is headquartered in Cambridge, Massachusetts.</p>
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Reclassifications</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain prior year amounts have been reclassified to conform with the current year presentation. </p>
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America require management to make estimates and assumptions that affect certain reported amounts and disclosures. These estimates and assumptions are reviewed on an on-going basis and updated as appropriate. Actual results could differ from those estimates. The Company&#8217;s significant estimates include the allowance for doubtful accounts, deferred tax valuation allowances, warranty obligations and reserves for slow-moving and consigned inventory.</p>
CY2019Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5600000
CY2019Q2 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
429459
CY2018Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
426727
CY2019Q2 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
632887
CY2018Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
1027757
CY2019Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
23750
CY2019Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
290782
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
288943
CY2019Q1 us-gaap Inventory Net
InventoryNet
171514
CY2019Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
656464
CY2019Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-45412973
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6629165
CY2019Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
26769
CY2018Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
46261
CY2018Q4 us-gaap Other Inventory Materials Supplies And Merchandise Under Consignment
OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment
135635
CY2019Q2 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
346427
CY2018Q4 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
149253
CY2019Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
373196
CY2018Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
331149
CY2019Q2 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
24000
CY2018Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
24000
CY2018Q4 myo Inventory Reserves Under Consignment
InventoryReservesUnderConsignment
51000
CY2019Q2 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
6361649
CY2018Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
3661
us-gaap Stock And Warrants Issued During Period Value Preferred Stock And Warrants
StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
196236
us-gaap Change In Unrealized Gain Loss On Fair Value Hedging Instruments1
ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
-141420
CY2019Q2 us-gaap Derivative Liabilities
DerivativeLiabilities
58477
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
8854
us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
0
us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
0
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
102500
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
30500
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
176500
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
237000
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.6324
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.6045
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.6253
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.6045
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0193
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0294
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0217
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0294
CY2019Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y7M6D
CY2018Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y8M4D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y5M15D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y8M4D
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.53
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.08
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.64
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.14
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
593353
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
492080
us-gaap Revenue From Related Parties
RevenueFromRelatedParties
26000
us-gaap Revenue From Related Parties
RevenueFromRelatedParties
238500
CY2019Q2 us-gaap Accounts Receivable Related Parties
AccountsReceivableRelatedParties
0
CY2018Q4 us-gaap Accounts Receivable Related Parties
AccountsReceivableRelatedParties
0
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
235000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
232000
CY2019Q2 us-gaap Accounts Payable Related Parties Current And Noncurrent
AccountsPayableRelatedPartiesCurrentAndNoncurrent
42000
CY2018Q4 us-gaap Accounts Payable Related Parties Current And Noncurrent
AccountsPayableRelatedPartiesCurrentAndNoncurrent
54000

Files In Submission

Name View Source Status
0001564590-19-030866-index-headers.html Edgar Link pending
0001564590-19-030866-index.html Edgar Link pending
0001564590-19-030866.txt Edgar Link pending
0001564590-19-030866-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
myo-10q_20190630.htm Edgar Link pending
myo-20190630.xml Edgar Link completed
myo-20190630.xsd Edgar Link pending
myo-20190630_cal.xml Edgar Link unprocessable
myo-20190630_def.xml Edgar Link unprocessable
myo-20190630_lab.xml Edgar Link unprocessable
myo-20190630_pre.xml Edgar Link unprocessable
myo-ex311_8.htm Edgar Link pending
myo-ex312_9.htm Edgar Link pending
myo-ex321_7.htm Edgar Link pending
myo-ex322_6.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending